title: Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI.
abstract: The vitamin E and donepezil trial for the treatment of amnestic mild cognitive impairment (MCI) was conducted at 69 centers in North America; 24 centers participated in an MRI sub study. The objective of this study was to evaluate the effect of treatment on MRI atrophy rates; and validate rate measures from serial MRI as indicators of disease progression in multi center therapeutic trials for MCI. Annual percent change (APC) from baseline to follow-up was measured for hippocampus, entorhinal cortex, whole brain, and ventricle in the 131 subjects who remained in the treatment study and completed technically satisfactory baseline and follow-up scans. Although a non-significant trend toward slowing of hippocampal atrophy rates was seen in APOE is an element of 4 carriers treated with donepezil; no treatment effect was confirmed for any MRI measure in either treatment group. For each of the four brain atrophy rate measures, APCs were greater in subjects who converted to AD than non-converters, and were greater in APOE is an element of 4 carriers than non-carriers. MRI APCs and changes in cognitive test performance were uniformly correlated in the expected direction (all p<0.000). Results of this study support the feasibility of using MRI as an outcome measure of disease progression in multi center therapeutic trials for MCI.
authors: Department of Radiology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. jack.clifford@mayo.edu
authors: Clifford R
authors: CR
authors: Jack
authors: Ronald C
authors: RC
authors: Petersen
authors: Michael
authors: M
authors: Grundman
authors: Shelia
authors: S
authors: Jin
authors: Anthony
authors: A
authors: Gamst
authors: Chadwick P
authors: CP
authors: Ward
authors: Drahomira
authors: D
authors: Sencakova
authors: Rachelle S
authors: RS
authors: Doody
authors: Leon J
authors: LJ
authors: Thal
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000975:Antioxidants / Q000008:administration & dosage; D001284:Atrophy / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage; D003072:Cognition Disorders / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology*; D000077265:Donepezil; D005260:Female; D006624:Hippocampus / Q000187:drug effects / Q000473:pathology*; D006801:Humans; D015994:Incidence; D007189:Indans / Q000008:administration & dosage*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage*; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D014810:Vitamin E / Q000008:administration & dosage*
chemical_list: D000975:Antioxidants; D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D014810:Vitamin E; D000077265:Donepezil